Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders

• US 10,301,262 B2
• Filed: 06/21/2016
• Issued: 05/28/2019
• Est. Priority Date: 06/22/2015
• Status: Active Grant

• Current Assignee: Arena Pharmaceuticals Incorporated
• Original Assignee: Arena Pharmaceuticals Incorporated
• Inventors: Blackburn, Anthony C., Castro, Ryan O., Hadd, Mark Allen, Ma, You-An, Montalban, Antonio Garrido, Rueter, Jaimie Karyn, Selvey, Lee Alani, Shakya, Sagar Raj, Carlos, Marlon
• Primary Examiner(s): Coleman, Brenda L
• Application Number:
  US15/738,175
• Publication Number:
  US 20180186738A1
• Time in Patent Office: 1,071 Days
• Field of Search: 514411, 548439
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 17/10 Anti-acne agents
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07B 2200/13 Crystalline forms, e.g. polymorphs
• CPC Class Codes: C07C 279/12 being further substituted by nitrogen atoms not being part of nitro or nitroso groups
• CPC Class Codes: C07C 279/14 : being further substituted by carboxyl groups
• CPC Class Codes: C07D 209/94 : containing carbocyclic rings other than six-membered

Abstract

The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1) in the treatment of S1P₁ receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in the vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).

Claims

1. A crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid;

wherein said crystalline free-plate habit has a BET specific surface area of about 0.1 m²/g to about 5.0 m²/g.

2. The crystalline free-plate habit according to claim 1, having a BET specific surface area of about 0.6 m²/g to about 4.0 m²/g.

3. A crystalline free-plate habit according to claim 1 or 2, having a powder X-ray diffraction pattern comprising peaks, in terms of 2θ

, at 8.2°

±

0.2°

, 16.4°

±

0.2°

, and 20.5°

±

0.2°

.

4. The crystalline free-plate habit according to claim 1 or 2, having a powder X-ray diffraction pattern comprising peaks, in terms of 2θ

, at 8.2°

±

0.2°

, 16.4°

±

0.2°

, 20.5°

±

0.2°

, and 24.6°

±

0.2°

.

5. The crystalline free-plate habit according to claim 1 or 2, having a powder X-ray diffraction pattern comprising peaks, in terms of 2θ

, at 8.2°

±

0.2°

, 16.4°

±

0.2°

, 20.5°

±

0.2°

, 24.6°

±

0.2°

, 28.8°

±

0.2°

, and 37.3°

±

0.2°

.

6. The crystalline free-plate habit according to claim 1, having a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°

C. to 208.5°

C. at a scan rate of 10°

C./minute.

7. The crystalline free-plate habit according to claim 1, having a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°

C. to 208.1°

C. at a scan rate of 10°

C./minute.

8. The crystalline free-plate habit according to claim 1, having a differential scanning calorimetry trace conducted at a scan rate of 10°

C./minute comprising an endotherm substantially as depicted in any one of FIGS. 6 to 10 and FIGS. 22 to 25.

9. The crystalline free-plate habit according to claim 1, having a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.3% weight or less at 90% RH.

10. The crystalline free-plate habit according to claim 1, having:

1) a powder X-ray diffraction pattern comprising peaks, in terms of 2θ

, at 8.2°

±

0.2°

, 16.4°

±

0.2°

, 20.5°

±

0.2°

, and 24.6°

±

0.2°

;

2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°

C. to 208.5°

C. at a scan rate of 10°

C./minute;

3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.3% weight or less at 90% RH; and

/or

4) a BET specific surface area of about 0.6 m²/g to about 4.0 m²/g.

11. The crystalline free-plate habit according to claim 1, having:

1) a powder X-ray diffraction pattern comprising peaks, in terms of 2θ

, at 8.2°

±

0.2°

, 16.4°

±

0.2°

, 20.5°

±

0.2°

, 24.6°

±

0.2°

, 28.8°

±

0.2°

, and 37.3°

±

0.2°

;

2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°

C. to 208.1°

C. at a scan rate of 10°

C./minute;

3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.2% weight or less at 90% RH; and

/or

4) a BET specific surface area of about 0.6 m²/g to about 4.0 m²/g.

12. A composition comprising a crystalline free-plate habit of L-arginine salt of (R)-2-(7(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid according to claim 1.

13. A pharmaceutical composition comprising a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid according to claim 1 and a pharmaceutical excipient.

14. The pharmaceutical composition according to claim 13, wherein said pharmaceutical composition is suitable for oral administration.

47. The crystalline free-plate habit according to claim 1, having:

1) a powder X-ray diffraction pattern comprising peaks, in terms of 2θ

, at 8.2°

±

0.2°

, 16.4°

±

0.2°

, and 20.5°

±

0.2°

;

2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°

C. to 208.5°

C. at a scan rate of 10°

C./minute; and

/or

3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.3% weight or less at 90% RH.

48. A pharmaceutical composition comprising a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid according to claim 10, and a pharmaceutical excipient.

49. A pharmaceutical composition comprising a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid according to claim 11, and a pharmaceutical excipient.

50. A pharmaceutical composition comprising a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid according to claim 47, and a pharmaceutical excipient.

15. A method for preparing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, said method comprising the steps of:

a) forming a first mixture comprising L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, a water-miscible anti-solvent, and H₂O;

b) heating the first mixture to a first heating temperature to form a second mixture;

wherein said first heating temperature is about 79°

C. to about 85°

C.;

c) adding a first additional amount of said water-miscible anti-solvent to said second mixture while maintaining said first heating temperature to form a suspension;

d) cooling the suspension to a first cooling temperature and thereafter heating to a second heating temperature;

wherein said first cooling temperature is about 18°

C. to about 22°

C., and said second heating temperature is about 69°

C. to about 73°

C.;

e) cycling Step d) optionally one or more times, wherein the first cooling temperature at each cycle may be the same or different and the second heating temperature at each cycle may be the same or different; and

f) cooling said suspension to a final cooling temperature to form said crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid;

wherein said final cooling temperature is about 18°

C. to about 22°

C.

16. A method according to claim 15, for preparing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, said method comprising the steps of:

a) hydrolyzing a compound of Formula (IIa);

17. The method according to claim 16, wherein said hydrolyzing-step solvent comprises acetonitrile.

18. The method according to claim 16, wherein:

said compound of Formula (IIa) is;

19. The method according to any one of claims 16 to 18, wherein said hydrolyzing is conducted in the presence of a phosphate buffer at a pH of about 6.9 to about 8.1, wherein said phosphate buffer is a potassium phosphate buffer.

20. The method according to claim 16, wherein said hydrolyzing is conducted at a temperature of about 35°

C. to about 45°

C.

21. The method according to claim 16, wherein after said hydrolyzing, said (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is not isolated.

22. The method according to claim 21, wherein after said hydrolyzing, said (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is present in an amount of at least 40% as determined by HPLC.

23. The method according to claim 16, wherein forming said first mixture in Step b) comprises the step of adding L-arginine and H₂O, either together or separately in any order, to a salt-forming mixture comprising (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and said water-miscible anti-solvent to form said first mixture.

24. The method according to claim 23, wherein said adding L-arginine and H₂O is conducted under an inert atmosphere comprising nitrogen.

25. The method according to claim 16, wherein said water-miscible anti-solvent comprises a solvent selected from the group consisting of:

acetonitrile, acetone, tetrahydrofuran, and C₂-C₄ alkanol.

26. The method according to claim 16, wherein said water-miscible anti-solvent comprises 2-propanol.

27. The method according to claim 23, wherein prior to adding said L-arginine and H₂O, said salt-forming mixture comprises (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid and 2-propanol in a weight ratio of about 1.0:

6.0 to about 1.0;

8.0.

28. The method according to claim 23, wherein the molar ratio between (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L-arginine is about 1.0:

0.93 to about 1.0;

1.01.

29. The method according to claim 23, wherein the weight ratio of L-arginine and H₂O is about 1.0:

1.2 to about 1.0;

1.5.

30. The method according to claim 23, wherein said salt-forming mixture prior to said adding L-arginine is at a temperature of about 18°

C. to about 30°

C.

31. The method according to claim 23, wherein said salt-forming mixture comprises (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.0:

6.0;

0.25 to about 1.0;

8.0;

0.7.

32. The method according to claim 23, wherein said salt-forming mixture during said adding L-arginine is at a temperature of about 18°

C. to about 30°

C.

33. The method according to claim 16, wherein said second mixture is substantially a homogeneous solution.

34. The method according to claim 16, wherein the weight ratio of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to said first additional amount of 2-propanol is about 1.00:

5.95 to about 1.00;

6.25.

35. The method according to claim 16, wherein said first additional amount of said water-miscible anti-solvent is added during a first time point and a second time point.

36. The method according to claim 35, wherein about 8% to about 12% of said first additional amount of said water-miscible anti-solvent is added at said first time point.

37. The method according to claim 35, wherein said first additional amount of said water-miscible anti-solvent is added at said first time point to form a cloudy mixture.

38. The method according to claim 35, wherein prior to said second time point, a seed crystal of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is optionally added.

39. The method according to claim 35, wherein said first additional amount of said water-miscible anti-solvent is added at said second time point at a rate to complete the addition in about 1.00 hour or greater.

40. The method according to claim 16, wherein cooling said suspension to said first cooling temperature in Step e) is conducted at a rate of about 9°

C./hour to about 11°

C./hour.

41. The method according to claim 16, wherein said cycling in Step f) comprises said cycling Step e) two times.

42. The method according to claim 41, wherein said cycling Step e) two times comprises cooling the suspension to a first cycling cooling temperature, heating the suspension to a first cycling heating temperature, cooling the suspension to a second cycling cooling temperature, and heating the suspension to a second cycling heating temperature.

43. The method according to claim 42, wherein said first cycling cooling temperature is about 16°

C. to about 26°

C., said first heating cycling temperature is about 55°

C. to about 65°

C., said second cycling cooling temperature is about 26°

C. to about 36°

C., and said second cycling heating temperature is about 45°

C. to about 55°

C.

44. The method according to claim 16, wherein said cycling in Step f) comprises said cycling Step e) three times.

45. The method according to claim 44, wherein said cycling Step e) three times comprises:

cooling the suspension to a first cycling cooling temperature, heating the suspension to a first cycling heating temperature, cooling the suspension to a second cycling cooling temperature, heating the suspension to a second cycling heating temperature, cooling the suspension to a third cycling cooling temperature, and heating the suspension to a third cycling heating temperature.

46. The method according to claim 45, wherein said first cycling cooling temperature is about 16°

C. to about 26°

C., said first heating cycling temperature is about 66°

C. to about 76°

C., said second cycling cooling temperature is about 16°

C. to about 26°

C., said second cycling heating temperature is about 55°

C. to about 65°

C., said third cycling cooling temperature is about 26°

C. to about 36°

C., and said third cycling heating temperature is about 45°

C. to about 55°

C.